Related Experiment Video
Updated: Jan 5, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Probiotic Yeasts Inhibit Virulence of Non-albicans Candida Species
Lohith Kunyeit1,2,3, Nawneet K Kurrey4, K A Anu-Appaiah5,2
1Department of Microbiology and Fermentation Technology, CSIR-Central Food Technological Research Institute (CFTRI), Mysore, India.
Abstract:
Systemic infections of Candida species pose a significant threat to public health. Toxicity associated with current therapies and emergence of resistant strains present major therapeutic challenges. Here, we report exploitation of the probiotic properties of two novel, food-derived yeasts, Saccharomyces cerevisiae (strain KTP) and Issatchenkia occidentalis (strain ApC), as an alternative approach to combat widespread opportunistic fungal infections. Both yeasts inhibit virulence traits such as adhesion, filamentation, and biofilm formation of several non-albicans Candida species, including Candida tropicalis, Candida krusei, Candida glabrata, and Candida parapsilosis as well as the recently identified multidrug-resistant species Candida auris They inhibit adhesion to abiotic surfaces as well as cultured colon epithelial cells. Furthermore, probiotic treatment blocks the formation of biofilms of individual non-albicans Candida strains as well as mixed-culture biofilms of each non-albicans Candida strain in combination with Candida albicans The probiotic yeasts attenuated non-albicans Candida infections in a live animal. In vivo studies using Caenorhabditis elegans suggest that exposure to probiotic yeasts protects nematodes from infection with non-albicans Candida strains compared to worms that were not exposed to the probiotic yeasts. Furthermore, application of probiotic yeasts postinfection with non-albicans Candida alleviated pathogenic colonization of the nematode gut. The probiotic properties of these novel yeasts are better than or comparable to those of the commercially available probiotic yeast Saccharomyces boulardii, which was used as a reference strain throughout this study. These results indicate that yeasts derived from food sources could serve as an effective alternative to antifungal therapy against emerging pathogenic Candida species.IMPORTANCE Non-albicans Candida-associated infections have emerged as a major risk factor in the hospitalized and immunecompromised patients. Besides, antifungal-associated complications occur more frequently with these non-albicans Candida species than with C. albicans Therefore, as an alternative approach to combat these widespread non-albicans Candida-associated infections, here we showed the probiotic effect of two yeasts, Saccharomyces cerevisiae (strain KTP) and Issatchenkia occidentalis (ApC), in preventing adhesion and biofilm formation of five non-albicans Candida strains, Candida tropicalis, Candida krusei, Candida glabrata, Candida parapsilosis, and Candida auris The result would influence the current trend of the conversion of conventional antimicrobial therapy into beneficial probiotic microbe-associated antimicrobial treatment.
Insights
Novel food-derived yeasts, Saccharomyces cerevisiae (KTP) and Issatchenkia occidentalis (ApC), show probiotic potential against Candida infections. These yeasts inhibit virulence factors and protect against infections, offering an alternative to traditional antifungal therapies.
Area of Science:
- Microbiology and Infectious Diseases
- Probiotics and Gut Microbiome
- Antifungal Resistance
Background:
- Systemic Candida infections are a significant public health concern, exacerbated by drug toxicity and emerging resistant strains.
- Non-albicans Candida species, including multidrug-resistant Candida auris, are increasingly implicated in severe infections, particularly in immunocompromised patients.
- Current antifungal therapies face challenges due to toxicity and the rise of resistant Candida strains.
Purpose of the Study:
- To investigate the probiotic potential of food-derived yeasts, Saccharomyces cerevisiae (strain KTP) and Issatchenkia occidentalis (strain ApC), as an alternative to combat opportunistic Candida infections.
- To evaluate the efficacy of these probiotic yeasts in inhibiting virulence factors and preventing infections caused by various non-albicans Candida species.
Main Methods:
- Assessed the ability of S. cerevisiae (KTP) and I. occidentalis (ApC) to inhibit virulence traits (adhesion, filamentation, biofilm formation) of non-albicans Candida species in vitro.
- Tested probiotic yeast efficacy against Candida adhesion to abiotic surfaces and human colon epithelial cells.
- Evaluated probiotic yeast effectiveness in preventing single and mixed-culture biofilms, including Candida albicans.
- Utilized Caenorhabditis elegans models to assess the in vivo protective effects of probiotic yeasts against non-albicans Candida infections and gut colonization.
Main Results:
- Both S. cerevisiae (KTP) and I. occidentalis (ApC) significantly inhibited adhesion, filamentation, and biofilm formation of multiple non-albicans Candida species, including C. tropicalis, C. krusei, C. glabrata, C. parapsilosis, and C. auris.
- Probiotic yeasts demonstrated efficacy in preventing Candida adhesion to colon cells and blocking both individual and mixed-culture biofilms.
- In vivo studies with C. elegans showed that probiotic yeast exposure protected against non-albicans Candida infection and reduced gut colonization post-infection.
- The probiotic effects of the tested yeasts were comparable to or better than the commercial probiotic Saccharomyces boulardii.
Conclusions:
- Food-derived yeasts, S. cerevisiae (KTP) and I. occidentalis (ApC), possess significant probiotic properties effective against non-albicans Candida species.
- These yeasts offer a promising alternative to conventional antifungal therapies by inhibiting key virulence factors and providing protection in vivo.
- The findings support the development of microbe-associated antimicrobial treatments using beneficial yeasts for emerging Candida infections.

